Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Biomarker Correlates and Clinical Activity of Cevostamab in Patients (pts) with Triple-Class Refractory Multiple Myeloma (MM) Who Have Received ≥1 Prior B-Cell Maturation Antigen (BCMA)-Targeted Bispecific Antibody (BsAb): Results from the Phase I/II CAMMA 2 Study

Michel Delforge, Joshua Richter, Yael C. Cohen, Paolo Corradini, Douglas W Sborov, Alexander M. Lesokhin, Jesus G Berdeja, Moshe E Gatt, Laura Paris, Laura Rosinol Dachs, Hang Quach, Manisha Kanwar, Olivier Catalani, Paresh Sewpaul, Elisabeth Wassner-Fritsch, Ameet Mishra, Kerstin Trunzer, Shaji Kumar

Blood (2024) 144 (Supplement 1): 4732.

https://doi.org/10.1182/blood-2024-199519

Published: 2024

Journal Articles

Zinpentraxin Alfa Reduces Myelofibrosis in a JAK2 -V617F Mouse Model of Myeloproliferative Neoplasms

Shivam Rai, Hui Hao-Shen, Stefan Dirnhofer, Julien Roux, Rajbharan Yadav, Anamarija Pfeiffer, Jakob Vowinckel, Audrey Arjomandi, Brian Higgins, Lyrialle Han, Kerstin Trunzer, Pontus Lundberg, Radek C. Skoda

Blood (2023) 142 (Supplement 1): 1787.

https://doi.org/10.1182/blood-2023-186631

Published: 2023

Journal Articles

Quantitative Analysis of Bone Marrow Features Highlights Heterogeneity in Myelofibrosis Patients Treated with Zinpentraxin Alfa in a Phase II Clinical Study

Hosuk Ryou, Korsuk Sirinukunwattana, Ruby Wood, Alan Aberdeen, Jens Rittscher, Olga Weinberg, Robert Hasserjian, Olga Pozdnyakova, Frank Peale, Brian Higgins, Pontus Lundberg, Kerstin Trunzer, Claire N Harrison, Daniel Royston

Blood (2023) 142 (Supplement 1): 4558.

https://doi.org/10.1182/blood-2023-181784

Published: 2023

Journal Articles

Prognostic value of MRD in CLL patients with comorbidities receiving chlorambucil plus obinutuzumab or rituximab

Anton W. Langerak, Matthias Ritgen, Valentin Goede, Sandra Robrecht, Jasmin Bahlo, Kirsten Fischer, Michael Steurer, Marek Trněný, Stephen P. Mulligan, Ulrich J. M. Mey, Kerstin Trunzer, Günter Fingerle-Rowson, Kathryn Humphrey, Stephan Stilgenbauer, Sebastian Böttcher, Monika Brüggemann, Michael Hallek, Michael Kneba, Jacques J. M. van Dongen

Blood (2019) 133 (5): 494–497.

https://doi.org/10.1182/blood-2018-03-839688

Published: 2019

Includes: Supplemental data

Journal Articles

Safety and Efficacy of Obinutuzumab Plus Fludarabine and Cyclophosphamide in Previously Untreated Patients with Chronic Lymphocytic Leukemia: Subgroup Analysis of the GREEN Study

Veronique Leblond, Guy Cantin, MD, Agostino Cortelezzi, Prof, Wolfgang Knauf, Mourad Tiab, Mehmet Turgut, MD, Andrey Zaritskey, Jean-Louis Merot, Kerstin Trunzer, Susan Robson, Ekaterina Gresko, Stephan Stilgenbauer, MD PhD, Robin Foà, Francesc Bosch

Blood (2017) 130 (Supplement 1): 3015.

https://doi.org/10.1182/blood.V130.Suppl_1.3015.3015

Published: 2017

Journal Articles

Safety and Efficacy Of Obinutuzumab (GA101) Plus CHOP Chemotherapy In First-Line Advanced Diffuse Large B-Cell Lymphoma: Results From The Phase 2 Gather Study (GAO4915g)

Andrew D Zelenetz, MD, PhD, Mehrdad Mobasher, MD, MPH, Luciano J Costa, MD, PhD, Ian Flinn, MD, PhD, Christopher R. Flowers, MD, MS, Mark S. Kaminski, MD, Thomas Sandmann, PhD, Kerstin Trunzer, PhD, Charlotte Vignal, MSc, PhD, Andres Forero-Torres, MD

Blood (2013) 122 (21): 1820.

https://doi.org/10.1182/blood.V122.21.1820.1820

Published: 2013

Journal Articles

Whole Exome Sequencing of CLL Before Second-Line Treatment with Fludarabine and Cyclophosphamide with or without Rituximab (REACH trial).

Nikola P Konstandin, Annika Dufour, PhD, Philipp A Greif, MD, Bianka Ksienzyk, Alexander Graf, Stefan Krebs, PhD, Helmut Blum, PhD, Stephanie Schneider, PhD, Karsten Spiekermann, MD, Wolfgang Hiddemann, MD, PhD, Kerstin Trunzer, PhD, Martin Weisser, MD, Stefan K Bohlander, MD

Blood (2012) 120 (21): 2514.

https://doi.org/10.1182/blood.V120.21.2514.2514

Published: 2012

NARROW

Biomarker Correlates and Clinical Activity of Cevostamab in Patients (pts) with Triple-Class Refractory Multiple Myeloma (MM) Who Have Received ≥1 Prior B-Cell Maturation Antigen (BCMA)-Targeted Bispecific Antibody (BsAb): Results from the Phase I/II CAMMA 2 Study

Zinpentraxin Alfa Reduces Myelofibrosis in a JAK2 -V617F Mouse Model of Myeloproliferative Neoplasms

Quantitative Analysis of Bone Marrow Features Highlights Heterogeneity in Myelofibrosis Patients Treated with Zinpentraxin Alfa in a Phase II Clinical Study

Prognostic value of MRD in CLL patients with comorbidities receiving chlorambucil plus obinutuzumab or rituximab

Safety and Efficacy of Obinutuzumab Plus Fludarabine and Cyclophosphamide in Previously Untreated Patients with Chronic Lymphocytic Leukemia: Subgroup Analysis of the GREEN Study

Safety and Efficacy Of Obinutuzumab (GA101) Plus CHOP Chemotherapy In First-Line Advanced Diffuse Large B-Cell Lymphoma: Results From The Phase 2 Gather Study (GAO4915g)

Whole Exome Sequencing of CLL Before Second-Line Treatment with Fludarabine and Cyclophosphamide with or without Rituximab (REACH trial).

Email alerts

ASH Publications

American Society of Hematology

Biomarker Correlates and Clinical Activity of Cevostamab in Patients (pts) with Triple-Class Refractory Multiple Myeloma (MM) Who Have Received ≥1 Prior B-Cell Maturation Antigen (BCMA)-Targeted Bispecific Antibody (BsAb): Results from the Phase I/II CAMMA 2 Study

Zinpentraxin Alfa Reduces Myelofibrosis in a JAK2 -V617F Mouse Model of Myeloproliferative Neoplasms

Quantitative Analysis of Bone Marrow Features Highlights Heterogeneity in Myelofibrosis Patients Treated with Zinpentraxin Alfa in a Phase II Clinical Study

Prognostic value of MRD in CLL patients with comorbidities receiving chlorambucil plus obinutuzumab or rituximab

Safety and Efficacy of Obinutuzumab Plus Fludarabine and Cyclophosphamide in Previously Untreated Patients with Chronic Lymphocytic Leukemia: Subgroup Analysis of the GREEN Study

Safety and Efficacy Of Obinutuzumab (GA101) Plus CHOP Chemotherapy In First-Line Advanced Diffuse Large B-Cell Lymphoma: Results From The Phase 2 Gather Study (GAO4915g)

Whole Exome Sequencing of CLL Before Second-Line Treatment with Fludarabine and Cyclophosphamide with or without Rituximab (REACH trial).

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only